Exploration of acetanilide derivatives of 1-(ω-phenoxyalkyl)uracils as novel inhibitors of Hepatitis C Virus replication
Magri A., Ozerov AA., Tunitskaya VL., Valuev-Elliston VT., Wahid A., Pirisi M., Simmonds P., Ivanov AV., Novikov MS., Patel AH.
<jats:title>Abstract</jats:title> <jats:p>Hepatitis C Virus (HCV) is a major public health problem worldwide. While highly efficacious directly-acting antiviral agents have been developed in recent years, their high costs and relative inaccessibility make their use limited. Here, we describe new 1-(ω-phenoxyalkyl)uracils bearing acetanilide fragment in 3 position of pyrimidine ring as potential antiviral drugs against HCV. Using a combination of various biochemical assays and <jats:italic>in vitro</jats:italic> virus infection and replication models, we show that our compounds are able to significantly reduce viral genomic replication, independently of virus genotype, with their IC<jats:sub>50</jats:sub> values in the nanomolar range. We also demonstrate that our compounds can block <jats:italic>de novo</jats:italic> RNA synthesis and that effect is dependent on a chemical structure of the compounds. A detailed structure-activity relationship revealed that the most active compounds were the N<jats:sup>3</jats:sup>-substituted uracil derivatives containing 6-(4-bromophenoxy)hexyl or 8-(4-bromophenoxy)octyl fragment at N<jats:sup>1</jats:sup> position.</jats:p>